Filing Details
- Accession Number:
- 0000939767-22-000114
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-17 20:46:10
- Reporting Period:
- 2021-05-17
- Accepted Time:
- 2022-11-17 20:46:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 939767 | Exelixis Inc. | EXEL | Biological Products, (No Disgnostic Substances) (2836) | 043257395 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1599803 | Jeffrey Hessekiel | C/O Exelixis, Inc. 1851 Harbor Bay Parkway Alameda CA 94502 | Evp, General Counsel & Sec | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-05-17 | 18,000 | $25.39 | 604,822 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 18,000 | $20.07 | 586,822 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-11-15 | 7,177 | $16.71 | 579,645 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 999 | Indirect | By 401(k) |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020.
- Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.09 to $25.71. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
- Includes 144,674 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 18 shares of common stock acquired on October 31, 2022, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
- Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.29. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
- Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 30, 2021.
- Includes 130,199 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of November 14, 2022.
Billionaire Hedge Funds
